Shares of Silence Therapeutics plc (LON:SLN – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 535 ($6.66) and traded as low as GBX 512 ($6.37). Silence Therapeutics shares last traded at GBX 535 ($6.66), with a volume of 913,528 shares traded.
Silence Therapeutics Stock Performance
The firm has a market capitalization of £480.35 million and a price-to-earnings ratio of -11.01. The stock’s fifty day moving average is GBX 535 and its two-hundred day moving average is GBX 535. The company has a quick ratio of 4.36, a current ratio of 4.52 and a debt-to-equity ratio of 0.80.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- What Are Dividend Champions? How to Invest in the Champions
- Comprehensive Analysis of PayPal Stock
- What Are Dividend Achievers? An Introduction
- Intuitive Surgical Stock Can Trend Much Higher This Year
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
